LKFT vs PRQR
Lakefront Biotherapeutics NV and ProQR Therapeutics N.v., side by side — 5 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | LKFT | PRQR |
|---|---|---|
| Revenue | €1.1B | €15.9M |
| Net income | €320.9M | €-42.2M |
| Gross margin | 97.3% | · |
| Net margin | 28.9% | −265.2% |
| Return on equity | 10.5% | −61.2% |
| Diluted EPS | €4.87 | −€0.40 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | €-271.2M | €-53.8M |
| Equity | · | €49.4M |
| Net debt / equity | · | −1.77× |
| Current ratio | 20.15× | 3.09× |
| Revenue CAGR 5y | 18.4% | · |
| Profit CAGR 5y | · | · |
LKFT bills 69.9× the revenue of PRQR, and PRQR closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
5 years side by side
| Fiscal year | LKFT | PRQR |
|---|---|---|
| FY2025 | €1.1B | €15.9M |
| FY2024 | €275.6M | €18.9M |
| FY2023 | €239.7M | €6.5M |
| FY2022 | €241.2M | €3.6M |
| FY2021 | €234.4M | €1.3M |
Bottom line
| Fiscal year | LKFT | PRQR |
|---|---|---|
| FY2025 | €320.9M | €-42.2M |
| FY2024 | €74.1M | €-27.8M |
| FY2023 | €211.7M | €-28.1M |
| FY2022 | €-218.0M | €-64.4M |
| FY2021 | €-103.2M | €-60.7M |
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +€1,096,342,000 | LKFT |
| FY2024 | +€256,744,000 | LKFT |
| FY2023 | +€233,210,000 | LKFT |
| FY2022 | +€237,655,000 | LKFT |
| FY2021 | +€233,049,000 | LKFT |
LKFT has reported the higher revenue in every one of these 5 fiscal years. The gap has widened since the earliest year compared.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PRQR's net margin has been more volatile than LKFT's over the 3 comparable fiscal years — 114.3 percentage points of standard deviation against 28.5.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LKFT led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PRQR's return on equity has been more volatile than LKFT's over the 11 comparable fiscal years — 17.0 percentage points of standard deviation against 12.3.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between LKFT and PRQR over these 11 fiscal years — LKFT led in 10 and PRQR in 1.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.